Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for SUNPHARMA
Revenue projections for SUNPHARMA

SUNPHARMA's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 0.000000
forwardPE 28.046993
debtToEquity 3.259000
earningsGrowth -0.195000
revenueGrowth 0.095000
grossMargins 0.782480
operatingMargins 0.243450
trailingEps 43.250000
forwardEps 32.680000

Sun Pharmaceutical Industries Limited's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
Sun Pharmaceutical Industries Limited's low growth in both earnings and revenue indicates the company's profits may decrease. This trend could signal a downturn in financial performance, suggesting that Sun Pharmaceutical Industries Limited might struggle to maintain its current profit levels.
SUNPHARMA's positive gross and operating margins reflect its profitability and efficiency. These metrics demonstrate the company's ability to manage costs effectively while generating strong revenue, highlighting its solid financial health and operational effectiveness.
SUNPHARMA's forward EPS is lower than its trailing EPS, indicating the company may experience reduced profitability. This signals that the company's earnings growth could slow down in the near future.

Price projections:

Price projections for SUNPHARMA
Price projections for SUNPHARMA

Sun Pharmaceutical Industries Limited's price projections have gradually declined, indicating growing uncertainty about the company's ability to meet previous targets. The downward trend reflects a more conservative view of Sun Pharmaceutical Industries Limited's future.

Recommendation changes over time:

Recommendations trend for SUNPHARMA
Recommendations trend for SUNPHARMA


SUNPHARMA has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see SUNPHARMA as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.